Clinical Trials Logo

Clinical Trial Summary

The goal of this trial is to evaluate the efficacy and the tolerance of the combination of nilotinib with chemotherapy in the front-line setting as induction and consolidation therapy in Ph+ ALL patient aged 55 years and over. A European consensus has been reached to adopt a common chemotherapeutic schedule for patients aged 55 years and over. This schedule will be used in this trial with the addition of nilotinib as concomitant therapy during induction, consolidation and maintenance. The patients will be prospectively monitored for minimal residual disease and bcr-abl tyrosine kinase domain mutations.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01528085
Study type Interventional
Source Goethe University
Contact
Status Completed
Phase Phase 2
Start date January 2012
Completion date March 10, 2020